Forum: Amerikaanse aandelen » Valeant Pharmaceuticals Intl Inc - VRX | DeBeurs.nl

Amerikaanse aandelen « Terug naar discussie overzicht

Valeant Pharmaceuticals Intl Inc - VRX

38 Posts, Pagina: 1 2 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
SimpleMind
0
Niet in portefeuille, maar een aandeel om de gaten te houden. Zwaar afgestraft de laatste maanden, zie chart. Van een high $250, naar nu $26 en een beetje. Bloed loopt door de straten, op deze niveaus is een herstelbeweging te verwachten. Echter hoog risico daar er geruchten gaan van chapter 11, men is druk in discussie met de kredietverleners, uitstel betalingen e.d.

finviz.com/quote.ashx?t=VRX&ty=c&...

www.google.com/finance?q=NYSE:VRX&...

26.98 -2.71 (-9.13%)
Mar 18 - Close
Currency in USD
Range 26.72 - 30.93
52 week 26.72 - 263.81
Vol / Avg. 58.85M/18.45M
Mkt cap 8.33B
P/E -
Div/yield -
EPS -0.77
Shares 341.19M
Beta 0.73
Inst. own 58%
Profitmaker
0
We gaan vuurwerk zien vandaag. De shorters gaan geroosterd worden.

Mooie squeeze kondigt zich aan!
Profitmaker
0
LAVAL, Quebec, April 5, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the ad hoc committee of the board of directors (the "Ad Hoc Committee") believes that its review of various Philidor and related accounting matters is complete, and that it has not identified any additional items that would require restatements beyond those required by matters previously disclosed. Given the completion of the review, Valeant's Board has determined to dissolve the Ad Hoc Committee and that the 12 independent directors on Valeant's Board, including the members of the Board's Audit and Risk Committee, will assume oversight responsibility for remaining work associated with the completion of the Company's current and restated financial statements and disclosures, as well as its assessment of related internal controls and remediation matters. As previously disclosed, the company intends to file its Form 10-K on or before April 29, 2016.Robert Ingram, chairman of the board and chair of the Ad Hoc Committee stated, "We appreciate the efforts of the Ad Hoc Committee and its independent advisors over the past five months. After conducting more than 70 interviews and reviewing over one million documents, the Ad Hoc Committee has not identified any additional items requiring restatements beyond those matters previously disclosed. We believe it is appropriate to transfer responsibility for any continuing work to the Board's independent directors. We continue to work diligently and are on schedule to file our Form 10-K on or before April 29, 2016." - See more at: www.eurobench.com/Forum/Topic/1308695...
Profitmaker
0
Ik zal eens opzoeken hoeveel aandeel er geshort zijn. Dit moet een enorme boost zijn voor het aandeel vandaag!
moonlightjorgo
0
[verwijderd]
0
Eindelijk de laatste paar handelsdagen wat verlies weg kunnen werken. Probeer wel hetzelfde aantal in portefeuille te houden. Dus op deze groene dagen kun je makkelijk wat ritjes maken.
[verwijderd]
0
SimpleMind
0
Het aandeel staat al bijna weer op haar 52wks low. Ziet er nog niet interessant uit om te kopen.

25.91 +0.98 (3.93%)
moonlightjorgo
0
StocksDaily TickerStreet WatchSoftware & TechnologyAbout »
Stock on Downward Trajectory: Valeant Pharmaceuticals International, Inc. (NYSE:VRX)
by Franklin Staff — May 15, 2016
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) stock has moved in a downward direction over the past month, causing some worry for investors. Based on a recent trade, the shares are down -19.96% for the month and -13.35% over the past five trading days. Looking further out, the stock is -74.52% year to date. With increased market volatility, stakeholders will likely be deciding whether or not now is a good time to unload the stock or hold for a turnaround.

Wall Street analysts are still seeing some upside to the stock despite the recent bearish move. Sell-side firms, on a consensus basis have a 2.90 recommendation, according to First Call. The recommendation is based on a 1 to 5 scale where 1 or 2 indicates a Buy recommendation, 3 a Hold and 4-5 a Sell.

Performance
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has posted trailing 12 months earnings of $-0.84 per share. The company has seen a change of -133.00% earnings per share this year. Analysts are predicting 22.87% for the company next year. The firm is yielding -0.60% return on assets and -4.60% return on equity.

Technicals
In taking a look at technical levels, shares are trading -30.14% away from the 50 day simple moving average and -77.57% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -90.18% away from it’s 52- week high and 9.98% away from its 52 week low. After the recent decrease, investors may also look to see if the stock has entered oversold territory and could possibly ripe for a bounceback. Traditionally a stock is considered to be oversold when the Relative Strength Index moves below 30. As of writing, Valeant Pharmaceuticals International, Inc.’s RSI stands at 35.22. In looking at volatility levels, the shares saw weekly volatility of 9.57% and 8.47% over the past month.

Disclaimer: This article is in no way encouraging or advising whether to buy or sell the security, Being a successful investor during one time period does not mean that you will make money when you actually invest during a later time period. Market conditions constantly change. When investing in securities or options you may lose all of the money you invested. Stock trading and investing involves risk of loss to investment capital and past performance is not a guarantee of future results.
38 Posts, Pagina: 1 2 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
627,80  -1,43  -0,23%  13:37
 AMS25-24h 627,71 -0,24%
 Germany30^ 13.760,00 +0,11%
 Dutch15-index 17.143,22 -0,10%
 BEL 20 4.190,97 +0,13%
 BRX20-24h 4.190,97 +0,13%
 Europe50^ 3.845,96 +0,13%
 Euro30-index 19.765,35 +0,13%
 US30# 29.436,77 +0,15%
 Nasd100# 9.657,58 +0,35%
 US500# 3.387,17 +0,25%
 Japan225# 23.511,77 -0,74%
 Gold World Spot (USD) 1.581,77 -0,13%
 New York WTI spot 56,22 +1,06%
 EUR/USD 1,0839 -0,01%

Stijgers

Ordina +8,33%
Air France-KLM +2,18%
Sif Holding +2,13%
NN Group +1,69%
SBM Offshore +1,37%

Dalers

Fagron -4,34%
BAM -2,56%
Kendrion -2,39%
ASMI -2,25%
BESI -2,17%